Quantcast

Latest Graft-versus-host disease Stories

2014-07-13 23:02:44

ReportsnReports.com adds “EpiCast Report Graft-Versus-Host Disease - Epidemiology Forecast to 2023” to its store. US will have the highest number of diagnosed incident cases of aGVHD in the 6MM, with 4,989 diagnosed incident cases. Dallas, Texas (PRWEB) July 13, 2014 Epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35%,...

2014-07-02 12:51:45

NIH/National Institute of Diabetes and Digestive and Kidney Diseases Adults stop anti-rejection drugs after stem-cell transplant reverses sickle cell disease NIH trial success suggests a new treatment option for older, sicker patients Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association. The...

2014-07-02 12:12:20

The JAMA Network Journals Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA. Myeloablative (use of high-dose chemotherapy or radiation) allogeneic hematopoietic stem cell transplantation (HSCT; receipt of hematopoietic stem cells "bone marrow" from another individual) is curative for children with severe sickle cell disease, but...

2014-06-17 12:25:17

Research demonstrates association between diversity of gut bacteria and survival WASHINGTON, June 17, 2014 /PRNewswire-USNewswire/ -- New research published online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. A healthy gastrointestinal tract contains a balanced community of...

2014-04-18 23:03:46

NewYork-Presbyterian/Columbia University Medical Center has opened the Irving Bone Marrow Transplant Unit, a state-of-the-art facility for comprehensive bone marrow transplant (BMT) care. The new unit features 18 inpatient rooms, a high-tech nurses station for individual patient monitoring, and a specialized airflow system to help protect patients with weakened immune systems. New York, NY (PRWEB) April 18, 2014 Irving Bone Marrow Transplant Unit Opens at NewYork-Presbyterian/Columbia...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

2014-03-24 04:22:05

AMSTERDAM, March 24, 2014 /PRNewswire/ -- Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that it will organize a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Milan, Italy. The satellite symposium hosted by Kiadis Pharma is entitled: "Effective T-cell immunotherapy with ATIR(TM) after...

2014-01-29 04:22:00

AMSTERDAM, January 29, 2014 /PRNewswire/ -- ~ Prof. Dr. Angela Krackhardt from the Klinikum rechts der Isar of the Technische Universitat Muenchen to lead the project ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that it has initiated a collaboration to identify and characterize leukemia-specific T-cells in Kiadis Pharma's lead product ATIR[TM], that would be responsible for the...

2013-12-09 14:08:58

Bortezomib (Velcade) reduces GVHD, boosts survival Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute. In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall...

2013-12-09 10:43:09

Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. HSCT is effectively used today as a form of "replacement"...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related